<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Extended-spectrum beta-lactamases</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Extended-spectrum beta-lactamases</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Extended-spectrum beta-lactamases</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">L Silvia Munoz-Price, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 10, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Extended-spectrum beta-lactamases (ESBLs) are enzymes that confer resistance to most beta-lactam antibiotics, including penicillins, cephalosporins, and the monobactam <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>. Infections with ESBL-producing organisms have been associated with poor outcomes.</p><p>Community and hospital-acquired ESBL-producing Enterobacteriaceae are prevalent worldwide [<a href="#rid1">1</a>]. Reliable identification of ESBL-producing organisms in clinical laboratories can be challenging, so their prevalence is likely underestimated. Carbapenems are the best antimicrobial agent for infections caused by such organisms.</p><p>The types and detection of extended-spectrum beta-lactamases as well as the epidemiology and treatment of organisms that produce them are discussed in this topic. The clinical features and diagnosis of the infections that ESBL-producing organisms often cause are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/7020.html" rel="external">"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired and ventilator-associated pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3122.html" rel="external">"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection"</a>.) </p><p class="headingAnchor" id="H2"><span class="h1">BETA-LACTAMASES</span><span class="headingEndMark"> — </span>Beta-lactamases are enzymes that open the beta-lactam ring, inactivating the antibiotic. The first plasmid-mediated beta-lactamase in gram-negative bacteria was discovered in Greece in the 1960s. It was named TEM after the patient from whom it was isolated (Temoniera) [<a href="#rid2">2</a>]. Subsequently, a closely related enzyme was discovered and named TEM-2. It was identical in biochemical properties to the more common TEM-1 but differed by a single amino acid with a resulting change in the isoelectric point of the enzyme.</p><p>These two enzymes are the most common plasmid-mediated beta-lactamases in gram-negative bacteria, including Enterobacteriaceae, <em>Pseudomonas aeruginosa</em>, <em>Haemophilus influenzae</em>, and <em>Neisseria gonorrhoeae</em>. TEM-1 and TEM-2 hydrolyze penicillins and narrow-spectrum cephalosporins, such as cephalothin or <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>. However, they are not effective against higher generation cephalosporins with an oxyimino side chain, such as <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>. Consequently, when these antibiotics were first introduced, they were effective against a broad group of otherwise resistant bacteria. A related but less common enzyme was termed SHV, because sulfhydryl reagents had a variable effect on substrate specificity. (See  <a class="medical medical_review" href="/z/d/html/479.html" rel="external">"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/480.html" rel="external">"Cephalosporins"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">EXTENDED-SPECTRUM BETA-LACTAMASES</span><span class="headingEndMark"> — </span>Not long after <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> came into clinical use in Europe, strains of <em>Klebsiella pneumoniae</em> were discovered in Germany with transferable resistance to the oxyimino-cephalosporins (eg, cefotaxime, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, and <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>) [<a href="#rid3">3</a>]. The enzyme responsible was related to SHV and was named SHV-2. TEM-related extended-spectrum beta-lactamases (ESBLs) were discovered in France in 1984 and in the United States in 1988.</p><p>The ESBL family is heterogeneous. SHV and TEM-type ESBLs arose by amino acid substitutions that allowed narrower-spectrum enzymes to attack the new oxyimino-beta-lactams. Others, notably members of the CTX-M family, represent plasmid acquisition of broad-spectrum beta-lactamases originally determined by chromosomal genes.</p><p>ESBLs vary in activity against different oxyimino-beta-lactam substrates but cannot attack the cephamycins (<a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">cefoxitin</a>, <a class="drug drug_general" data-topicid="9222" href="/z/d/drug information/9222.html" rel="external">cefotetan</a> and cefmetazole) and the carbapenems (<a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, and <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">ertapenem</a>). They are also generally susceptible to beta-lactamase inhibitors, such as clavulanate, sulbactam, and tazobactam, which consequently can be combined with a beta-lactam substrate to test for the presence of this resistance mechanism.</p><p>ESBLs have been found exclusively in gram-negative organisms, primarily in <em>Klebsiella pneumoniae</em>, <em>Klebsiella oxytoca</em>, and <em>Escherichia coli</em> but also in <em>Acinetobacter</em>, <em>Burkholderia</em>, <em>Citrobacter</em>, <em>Enterobacter</em>, <em>Morganella</em>, <em>Proteus</em>, <em>Pseudomonas</em>, <em>Salmonella</em>, <em>Serratia</em>, and <em>Shigella</em> spp.</p><p>Infection due to ESBL-producing <em>E. coli</em> has become widespread in hospitals around the world [<a href="#rid4">4</a>]. Community-associated infection due to ESBL has also been recognized as an important clinical problem in the United States and Europe. In addition, a substantial portion of community-onset infection due to ESBL-producing <em>E. coli</em> has been observed among patients with no discernible health care-associated risk factors [<a href="#rid5">5</a>]. </p><p class="headingAnchor" id="H4"><span class="h2">ESBL varieties</span></p><p class="headingAnchor" id="H2046954083"><span class="h3">TEM beta-lactamases</span><span class="headingEndMark"> — </span>The amino acid substitutions responsible for the ESBL phenotype cluster around the active site of the enzyme and change its configuration, allowing access to oxyimino-beta-lactam substrates. Single amino acid substitutions at positions 104, 164, 238, and 240 produce the ESBL phenotype, but ESBLs with the broadest spectrum usually have more than a single amino acid substitution. Based upon different combinations of changes, currently more than 220 TEM-type enzymes have been described. Not all behave as ESBL, and some, such as TEM-1 and TEM-2, only hydrolyze beta-lactams such as penicillins and narrow-spectrum cephalosporins [<a href="#rid6">6</a>]. Nevertheless, most are ESBLs, some are resistant to beta-lactamase inhibitors, and a few are both ESBLs and inhibitor-resistant. TEM-10, TEM-12, and TEM-26 are among the most common in the United States.</p><p class="headingAnchor" id="H6"><span class="h3">SHV beta-lactamases</span><span class="headingEndMark"> — </span>ESBLs in this family also have amino acid changes around the active site, most commonly at positions 238 or 238 and 240. More than 190 SHV varieties are known, and they are found worldwide. SHV-2, SHV-5, SHV-7, and SHV-12 are among the most common [<a href="#rid7">7</a>]. Not all the SHVs are ESBL and some, such as SHV-1, only hydrolyze beta-lactams such as penicillins and narrow-spectrum cephalosporins [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H62299411"><span class="h3">CTX-M beta-lactamases</span><span class="headingEndMark"> — </span>These enzymes were named for their greater activity against <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> than other oxyimino-beta-lactam substrates (eg, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>). Despite their name, a few are more active on ceftazidime than cefotaxime. Rather than arising by mutation, they represent examples of plasmid acquisition of beta-lactamase genes normally found on the chromosome of <em>Kluyvera</em> species, a group of rarely pathogenic commensal organisms. </p><p>More than 160 CTX-M enzymes have been described [<a href="#rid8">8</a>]. They have been found in many different Enterobacteriaceae including <em>Salmonella</em>, are the most common ESBL type worldwide [<a href="#rid9">9</a>], and are increasingly prevalent in the United States [<a href="#rid10">10</a>]. The proliferation of CTX-M enzymes is due not to being better beta-lactamases than TEM or SHV varieties but to the capture and dissemination of CTX-M genes by mobile genetic elements that mediate rapid and efficient spread between replicons and from cell to cell, especially to highly successful lineages such as <em>E. coli</em> ST131 and ST405 and <em>K. pneumoniae</em> CC11 and ST147 [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H8"><span class="h3">OXA beta-lactamases</span><span class="headingEndMark"> — </span>OXA beta-lactamases were long recognized as a less common but also plasmid-mediated beta-lactamase variety that could hydrolyze <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a> and related anti-staphylococcal penicillins. Amino acid substitutions in OXA enzymes can also give the ESBL phenotype. OXA-type ESBLs have been found mainly in <em>Pseudomonas aeruginosa</em> isolates from Turkey and France. OXA beta-lactamases with carbapenemase activity have also been described. (See  <a class="medical medical_review" href="/z/d/html/471.html" rel="external">"Carbapenem-resistant <i>E. coli</i>, <i>K. pneumoniae</i>, and other Enterobacterales (CRE)", section on 'Classifications and geographic distribution'</a>.)</p><p>Not all OXA enzymes are ESBLs, and certain ones only hydrolyze beta-lactams such as penicillins, antistaphylococcal penicillins, and narrow-spectrum cephalosporins [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H1535778883"><span class="h3">Others</span><span class="headingEndMark"> — </span>Other plasmid-mediated ESBL families, such as PER, VEB, and GES, have been described but are uncommon and have been found mainly in <em>P. aeruginosa</em> and at a limited number of geographic sites [<a href="#rid12">12</a>]. In addition to conferring high-level resistance to antipseudomonal beta-lactams, these ESBLs also degrade cephalosporins, and monobactams. Other rare ESBLs found in Enterobacteriaceae are BES, SFO, and TLA. (See  <a class="medical medical_review" href="/z/d/html/3135.html" rel="external">"Principles of antimicrobial therapy of Pseudomonas aeruginosa infections"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">LABORATORY DETECTION</span><span class="headingEndMark"> — </span>Detection of extended-spectrum beta-lactamases (ESBLs) is based upon the resistance they confer to oxyimino-beta-lactam substrates (eg, <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>) and the ability of a beta-lactamase inhibitor, usually clavulanate, to block this resistance. Other enzymes have different features that can be misleading in the laboratory. AmpC-type beta-lactamases, which are now determined by plasmid as well as chromosomal genes, can provide oxyimino-beta-lactam resistance, but they are resistant to inhibition by clavulanate and usually confer resistance to cephamycins (eg, <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">cefoxitin</a>, <a class="drug drug_general" data-topicid="9222" href="/z/d/drug information/9222.html" rel="external">cefotetan</a>, and cefmetazole), which ESBLs do not.</p><p>Problems in identification arise because ESBLs are heterogeneous. OXA-type ESBLs, for example, are poorly inhibited by clavulanate. Some ESBLs are best detected with <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> and others with <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> (such as most CTX-M enzymes). Consequently, susceptibility to several oxyimino-beta-lactams must be tested; criteria for ESBL detection have changed over time; and clinical laboratories vary in their success in diagnosis.</p><p>Previously, the Clinical and Laboratory Standards Institute (CLSI) recommended screening isolates of <em>E. coli</em>, <em>K. pneumoniae</em>, <em>K. oxytoca</em>, or <em>Proteus mirabilis</em> by disk diffusion or broth dilution for resistance, followed by a confirmatory test for increased susceptibility in the presence of clavulanate [<a href="#rid13">13</a>]. In 2010, however, the CLSI published new minimum inhibitory concentration (MIC) and disk diffusion breakpoints for the Enterobacteriaceae [<a href="#rid14">14</a>]. The new MIC breakpoints are one to three doubling dilutions lower than the original breakpoints, and the new disk diffusion criteria include larger zone diameters than those in previous guidelines. In 2010, the European Committee on Antimicrobial Susceptibility Testing (EUCAST) similarly changed the breakpoint criteria for susceptibility [<a href="#rid15">15</a>]. Thus, many organisms that previously would have been categorized as susceptible using the former breakpoints may now be considered intermediate or resistant [<a href="#rid16">16</a>]. Whether the evidence for these new breakpoints is sufficient [<a href="#rid17">17</a>] and if they eliminate the need to perform ESBL screening and confirmatory tests for making treatment decisions is controversial [<a href="#rid18">18</a>]. While the disk diffusion breakpoints can be implemented immediately, there are barriers to immediate implementation of the new MIC breakpoints; clinicians should review local practices with their own microbiology laboratories.</p><p>Nonetheless, ESBL testing may be performed for infection control purposes [<a href="#rid19">19</a>]. In addition to disk diffusion and broth dilution techniques, other techniques for ESBL detection include:</p><p class="bulletIndent1"><span class="glyph">●</span>Automated systems (Vitek, MicroScan, and BD Diagnostics)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The double disk test, in which a disk with clavulanate placed near a disk with an oxyimino-beta-lactam enhances susceptibility to the latter compound</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An E-test strip with clavulanate added to one side of a dual oxyimino-beta-lactam gradient</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pyrosequencing and microarray technologies [<a href="#rid20">20</a>]</p><p></p><p>Identification of the ESBL type present in a particular strain is generally a task for a research laboratory.</p><p class="headingAnchor" id="H11"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H12"><span class="h2">Distribution</span><span class="headingEndMark"> — </span>Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae have been reported worldwide, most often in hospital specimens but also in samples from the community. Prevalence rates vary from hospital to hospital and from country to country as illustrated by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>In a sample of 5739 isolates from 72 US hospitals collected in 2012, the overall frequency of ESBLs was 16 percent in <em>K. pneumoniae</em>, 11.9 percent in <em>E. coli</em>, 10 percent in <em>K. oxytoca</em>, and 4.8 percent in <em>P. mirabilis </em>[<a href="#rid21">21</a>]. CTX-M-15 was the most common ESBL identified, followed by SHV- and TEM-type enzymes. Two or more β-lactamase genes were identified in 63 percent of the isolates, including non-ESBLs and carbapenemases.</p><p></p><p class="bulletIndent1">Rates of ESBLs have also been increasing in the US, as reflected by a study that reported an increase in the incidence of ESBL-producing infections in southeastern US hospitals from 11.1 to 22.1 infections per 100,000 patient days between 2009 and 2014 [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ESBL prevalence is even higher in isolates from Asia, Latin America, and the Middle East [<a href="#rid23">23</a>], reaching 60 percent in <em>K. pneumoniae</em> isolates from Argentina and 48 percent in <em>E. coli</em> isolates from Mexico [<a href="#rid24">24,25</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing community-acquired ESBL infections led to the discovery of concomitant high and increasing rates of fecal colonization by ESBL-producing bacteria worldwide [<a href="#rid26">26,27</a>].</p><p></p><p>Children are also increasingly affected by ESBL-producing organisms [<a href="#rid28">28</a>]. In a surveillance study from the US, the prevalence of ESBL-producing gram-negative rod isolates in pediatric specimens increased from 0.28 percent in 1999 to 2001 to 0.92 percent in 2010 to 2011 [<a href="#rid29">29</a>].</p><p>When the frequency of ESBL-positive isolates is high in a single institution, it is more likely that a single ESBL type is involved. Outbreaks have been due both to a single ESBL-producing strain and to a single ESBL plasmid carried by unrelated strains. A resistant strain or plasmid may cause problems in several hospitals locally or involve a large geographic area. Community clinics and nursing homes have also been identified as potential reservoirs for ESBL-producing <em>K. pneumoniae</em> and <em>E. coli</em> [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H18777551"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>Although ESBL-producing organisms are a growing cause of nosocomial infections and outbreaks as well as community-acquired infections, data on the actual risk of transmission of ESBLs within and outside the hospital setting are limited.</p><p>In one observational study from a tertiary care hospital in Switzerland, active surveillance cultures for ESBL carriage were performed in patients who shared a hospital room for at least 24 hours (contact patients, n = 133) with patients found to be infected or colonized with an ESBL-producing organism (index patients, n = 93) [<a href="#rid31">31</a>]. Only seven contacts (5.3 percent) were found to be colonized with an ESBL-producing organism, and only two harbored a strain that was genetically identical to that in the index patient, suggesting a low overall transmission rate (1.5 percent). </p><p>A study from a separate tertiary care hospital in Switzerland reported slightly higher in-hospital transmission rates of 4.5 percent for ESBL-producing <em>E. coli</em> (4 of 88 contacts exposed to 40 index patients) and 8.3 percent for ESBL-producing <em>K. pneumoniae</em> (2 of 24 contacts exposed to 8 index patients) [<a href="#rid32">32</a>]. Even higher rates of transmission were observed among household contacts of index patients (23 and 25 percent for <em>E. coli</em> and <em>K. pneumoniae</em>, respectively). One report described a household in which two young children had ESBL-producing <em>E. coli</em> urinary tract infections, and all four of the other household members had intestinal colonization with the same strain [<a href="#rid33">33</a>].</p><p>Additionally, environmental, animal, and food contamination with ESBL-producing gram-negative organisms has been extensively documented. As examples, ESBL producers have been detected in city rivers (eg, the River Thames in London, England), sewage [<a href="#rid34">34,35</a>], sink pipes [<a href="#rid36">36</a>], wild seagulls (eg, in Porto and Miami Beach [<a href="#rid37">37,38</a>]), livestock [<a href="#rid39">39,40</a>], and companion animals [<a href="#rid41">41,42</a>]. Alarmingly, ESBL-producing gram-negative organisms have also been identified in retail meat obtained from supermarkets [<a href="#rid43">43-45</a>]. A foodborne nosocomial outbreak among 156 patients in Spain provided evidence that food can be a transmission vector for ESBL-producing Enterobacteriaceae [<a href="#rid46">46</a>]. Up to 35 percent of the kitchen surfaces were colonized, and 14 percent of food handlers were fecal carriers of a single strain of SHV-1 and CTX-M-15 producing <em>K. pneumoniae</em>. </p><p class="headingAnchor" id="H13"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>The gastrointestinal tract is the main reservoir for ESBL-producing Enterobacteriaceae, and colonization with such organisms is a strong risk factor for subsequent infection with them. Most clinical factors associated with colonization and infection with ESBL-producing organisms involve healthcare exposure, such as hospitalization, residence in a long-term care facility, hemodialysis use, and presence of an intravascular catheter [<a href="#rid6">6,47-51</a>]. However, community-acquired infections are not uncommon; risk factors for these include recent antibiotic therapy, use of corticosteroids, and the presence of a percutaneous feeding tube [<a href="#rid52">52</a>]. </p><p>Additionally, for individuals living in the United States and Europe, travel to Asia has emerged as a major risk factor for colonization with ESBL-producing Enterobacteriaceae [<a href="#rid53">53-57</a>]. As an example, in a study of Dutch individuals who had no ESBL colonization prior to international travel, 34 percent overall and 75 percent of those who went to southern Asia acquired ESBL colonization following their travels. Colonization persisted for 30 days, on average, and 11 percent remained colonized after a year [<a href="#rid54">54</a>]. Among travelers, travelers’ diarrhea and antibiotic use has been associated with an increased risk of ESBL acquisition [<a href="#rid57">57</a>]. </p><p>Predicting when an Enterobacteriaceae infection is with an ESBL-producing isolate, though, remains difficult. In one retrospective study from the United States, among 1288 cases of bacteremia, the features most strongly associated with ESBL infection (detected in 15 percent) were prior history of ESBL colonization or infection in the prior six months and colonization with an ESBL isolate [<a href="#rid58">58</a>]. Incorporation of these features, in addition to the presence of a chronic indwelling vascular device, age ≥43 years, and six or more days of antibiotic exposure within the prior six months, into a decision tree was able to identify ESBL-producing infections with a positive and negative predictive value of 91 and 92 percent, respectively.</p><p class="headingAnchor" id="H14"><span class="h1">TREATMENT OPTIONS</span></p><p class="headingAnchor" id="H533944167"><span class="h2">Preferred agents</span><span class="headingEndMark"> — </span>The preferred, proven therapeutic options for severe infections caused by extended-spectrum beta-lactamase (ESBL)-producing organisms are carbapenems (<a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, and <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">ertapenem</a>). We use meropenem or imipenem for most ESBL infections. Ertapenem is an acceptable option in the absence of resistance or severe sepsis and can be particularly useful in the outpatient setting. (See <a class="local">'Carbapenems'</a> below.)</p><p>The combination cephalosporin-beta-lactamase inhibitor agents (<a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> and <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>) and the broad-spectrum <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a> <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">eravacycline</a> appear promising [<a href="#rid59">59-62</a>], although data on their clinical efficacy are too limited at this time to recommend their routine use, and it is not clear that they provide additional benefit over carbapenems. In the United States, ceftolozane-tazobactam, ceftazidime-avibactam, and eravacycline have been approved by the US Food and Drug Administration (FDA) for use in complicated intra-abdominal infections (with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> for the cephalosporin-beta-lactamase inhibitor combinations). Ceftolozane-tazobactam and ceftazidime-avibactam are also approved for complicated urinary tract infections (UTIs); trials evaluating their use for treatment of ventilator-associated pneumonia are ongoing. Eravacycline was not successful in trials for complicated UTIs. (See <a class="local">'Cephalosporins'</a> below and <a class="local">'Other drugs'</a> below.)</p><p>For complicated UTI, <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">plazomicin</a> is another option that can be active against ESBL-producing isolates that are resistant to other aminoglycosides. We generally reserve this for patients who cannot use a carbapenem, and risk of renal dysfunction is a consideration. Similarly, parenteral <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a> is a potential option for complicated UTI due to susceptible ESBL-producing isolates when carbapenems cannot be used, but it is not widely available. (See <a class="local">'Other drugs'</a> below.)</p><p>For simple cystitis, oral <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">fosfomycin</a> and <a class="drug drug_general" data-topicid="9704" href="/z/d/drug information/9704.html" rel="external">nitrofurantoin</a> are other potential options that may retain activity against ESBL-producing isolates. These are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">"Acute simple cystitis in adult and adolescent females", section on 'Patients with MDR risk factors'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">In vitro susceptibility</span><span class="headingEndMark"> — </span>ESBL-producing organisms vary in their susceptibility to different oxyimino-beta-lactams; despite resistance to some, they may appear sensitive to others. Strains making TEM and SHV-type ESBLs usually appear susceptible to <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> and to <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, but both drugs show an inoculum effect with diminished susceptibility as the inoculum is raised from 10<sup>5</sup> to 10<sup>7</sup> organisms [<a href="#rid63">63</a>]. Some CTX-M- and OXA-type ESBLs test resistant to cefepime despite use of a low inoculum.</p><p>Strains producing only ESBLs test susceptible to cephamycins (eg, <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">cefoxitin</a>, <a class="drug drug_general" data-topicid="9222" href="/z/d/drug information/9222.html" rel="external">cefotetan</a>, and cefmetazole) and carbapenems in vitro and show little if any inoculum effect with these agents [<a href="#rid64">64</a>].</p><p>ESBL-producing isolates typically show greater than average resistance to other agents including aminoglycosides and fluoroquinolones. These relationships were illustrated in a review of 85 episodes of bacteremia due to ESBL-producing <em>K. pneumoniae</em> from 12 hospitals in seven countries [<a href="#rid65">65</a>]. All isolates were susceptible to <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> or <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, while 71 percent were resistant to <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, 47 percent to <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, and 20 percent to <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>.</p><p class="headingAnchor" id="H16"><span class="h2">Clinical efficacy</span><span class="headingEndMark"> — </span>The choice of an appropriate antibiotic is essential since failure to treat with an antibiotic active against ESBL-producing <em>K. pneumoniae</em> is associated with lack of an adequate response and increased mortality [<a href="#rid65">65,66</a>]. The potential magnitude of this effect was illustrated in a review of 85 patients with ESBL-producing <em>K. pneumoniae</em> infection from 12 hospitals in seven countries; 20 patients (24 percent) died [<a href="#rid65">65</a>]. Failure to treat with an antibiotic that had in vitro activity against the cultured isolate during the first five days after the culture result was known was associated with a significantly higher mortality rate compared with treatment with active antibiotics (64 versus 14 percent). Administration of a carbapenem (<a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, and perhaps <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">ertapenem</a>) alone or with other antibiotics was associated with a significantly lower mortality than for those treated with active noncarbapenem antibiotics.</p><p class="headingAnchor" id="H17"><span class="h3">Carbapenems</span><span class="headingEndMark"> — </span>Treatment with a carbapenem produces the best outcomes in terms of survival and bacteriologic clearance. The efficacy of therapy with these agents is supported by a randomized trial in which <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> resulted in lower mortality rates compared with <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> among patients with bacteremia with ESBL-producing Enterobacteriaceae [<a href="#rid67">67</a>]. (See <a class="local">'Piperacillin-tazobactam'</a> below.) </p><p>Preferential use of carbapenems is also supported by observational studies [<a href="#rid65">65,68,69</a>]. In a prospective study of 85 episodes of bacteremia due to ESBL-producing <em>K. pneumoniae</em>, there was only one death at 14 days among 27 patients (3.7 percent mortality) treated with carbapenem monotherapy (<a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> in 24 and <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> in 3) [<a href="#rid65">65</a>]. In contrast, there were seven deaths among the 11 patients (64 percent) who did not receive any antibiotic active against these organisms and four deaths in nine patients (44 percent) treated with cephalosporin monotherapy or a beta-lactam/beta-lactamase inhibitor combination such as <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>. On multivariate analysis, carbapenem use was independently associated with reduced mortality (odds ratio 0.09, 95% CI 0.01-0.65). Similarly, in a retrospective study of patients with bacteremia due to an ESBL-producing organism, 14-day mortality was 8 percent among the 110 who received a carbapenem for empiric treatment compared with 17 percent among the 103 who received piperacillin-tazobactam [<a href="#rid69">69</a>]. </p><p>There are no clear differences in efficacy between <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> and <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>. The choice to use one over the other is predominantly based on toxicity profiles in specific hosts. As an example, meropenem is favored in the setting of seizures or pregnancy because of the possible central nervous system toxicity and unknown safety in pregnancy of imipenem. Meropenem also may be easier to dose in the setting of changing or impaired renal failure. (See  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Carbapenems'</a>.)</p><p><a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">Ertapenem</a> has the advantage of once-daily dosing and has good in vitro activity [<a href="#rid64">64</a>], and clinical data regarding its use are growing [<a href="#rid70">70-75</a>]. In two retrospective studies from the United States and Taiwan of patients with bloodstream infections due to Enterobacteriaceae that produced ESBL, treatment with ertapenem (n = 72 and 75, respectively) was associated with similar mortality rates as treatment with <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> or <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> (n = 132 and 176) [<a href="#rid70">70,71</a>]. Although patients treated with ertapenem in the study from the US had less invasive disease and a lower frequency of severe sepsis, adjusted analysis controlling for disease state and severity still showed equivalent mortality rates in the two groups. Smaller studies have reported favorable clinical response and microbiologic cure rates using ertapenem for ventilator-associated pneumonia and UTIs due to ESBL-producing organisms [<a href="#rid72">72-74</a>]. However, some ESBL-producing isolates are resistant to ertapenem, and resistance may also develop on therapy [<a href="#rid72">72,76</a>]. We reserve the use of ertapenem for infections with susceptible ESBL-producing organisms that are not associated with severe sepsis. It can be a useful alternative for outpatient treatment of such infections. (See  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Ertapenem'</a>.)</p><p class="headingAnchor" id="H18"><span class="h3">Cephalosporins</span><span class="headingEndMark"> — </span>Treatment of severe infections due to ESBL-producing <em>K. pneumoniae</em> with an oxyimino-beta-lactam (eg, <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, or <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>) is likely to result in treatment failure, even if the organism demonstrates in vitro susceptibility [<a href="#rid65">65,66,77</a>]. However, cephalosporin-beta-lactamase inhibitor combinations (namely <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> and <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>) are novel agents that appear to have greater activity against ESBL-producing organisms [<a href="#rid78">78</a>]. (See  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Ceftolozane-tazobactam'</a> and  <a class="medical medical_review" href="/z/d/html/482.html" rel="external">"Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Ceftazidime-avibactam'</a>.)</p><p>In a review of 28 patients with ESBL-producing <em>Klebsiella pneumoniae</em> with reported susceptibility to cephalosporins, 15 failed to respond to standard-spectrum cephalosporin therapy (ie, not novel, expanded-spectrum cephalosporins) [<a href="#rid66">66</a>]. A possible explanation for the inferior outcomes in patients treated with apparently active cephalosporins may be the inoculum effect, in which there is a marked increase in minimum inhibitory concentration (MIC) with increased inoculum [<a href="#rid63">63</a>]. Additionally, although ESBL-producing bacteria generally test susceptible to cephamycins, resistance has developed after their use due to loss of porin channels for cephamycin entry, and there is little clinical experience to demonstrate their efficacy.</p><p>Most available data do not encourage <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> use for ESBL-producing pathogens [<a href="#rid79">79</a>]. Although some observational data have suggested that high-dose cefepime (eg, 2 g every eight hours) can be effective [<a href="#rid80">80-82</a>], in a randomized trial of patients with UTI caused by ESBL-producing pathogens, treatment failure with cefepime was higher than with <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">ertapenem</a> or <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> [<a href="#rid83">83</a>]. Similarly, in a retrospective study, definitive cefepime therapy for monomicrobial bacteremia due to ESBL-producing Enterobacteriaceae with an MIC ≤8 mcg/mL was associated with a higher rate of clinical and microbiologic failure and mortality compared with carbapenem therapy [<a href="#rid77">77</a>]. Among those treated with cefepime, mortality rates due to sepsis rose as the MIC exceeded 1 mcg/mL. </p><p>With the addition of a beta-lactamase inhibitor, <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> and <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> have extended spectra of activity to include most ESBL-producing Enterobacteriaceae [<a href="#rid84">84,85</a>]. As an example, in a trial of patients with intraabdominal infections, ceftolozane-tazobactam plus <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> compared favorably with <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> among those who had infections with ESBL-producing organisms (clinical cure rate in 23 of 24 [95 percent] versus 23 of 26 [89 percent] with meropenem) [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H20"><span class="h3">Piperacillin-tazobactam</span><span class="headingEndMark"> — </span>We do not recommend <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> for severe infections with ESBL-producing organisms. However, piperacillin-tazobactam may be effective and a reasonable alternative for isolated UTIs due to ESBL-producing organisms given the much higher drug concentrations achieved in the urine compared with plasma [<a href="#rid86">86</a>].</p><p>Although some ESBL isolates have MICs for <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> that are in the susceptible range, treatment of serious infections with piperacillin-tazobactam appears to result in worse outcomes than with a carbapenem. In an international, randomized, open-label trial of 379 adults with bacteremia due to <em>E. coli</em> or <em>Klebsiella</em> species that were nonsusceptible to <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> or <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a> (most confirmed to produce an ESBL), the 30-day, all-cause mortality rate was higher with directed therapy with piperacillin-tazobactam compared with <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (12.3 versus 3.7 percent) [<a href="#rid67">67</a>]. There was also a trend toward higher rates of clinical and microbiologic resolution by day 4 with meropenem (75 versus 68 percent with piperacillin-tazobactam, although the difference was not statistically significant). The vast majority of isolates tested susceptible to piperacillin-tazobactam (median MIC 2 mcg/mL; interquartile range 1.5 to 4), and there was no relationship between mortality and MIC value. This study had a number of limitations, including the lack of blinding of treating clinicians and investigators, the variable empiric regimens used prior to randomization, and an imbalance in patient characteristics between groups. Nevertheless, the findings support our suggestion not to use piperacillin-tazobactam for serious infections with ESBL-producing bacteria. A recent multicenter, randomized controlled trial of 72 patients with AmpC beta-lactamase-producing gram-negative rod bacteremia, compared <a class="drug drug_general" data-topicid="9775" href="/z/d/drug information/9775.html" rel="external">piperacillin</a> tazobactam against meropenem [<a href="#rid87">87</a>]. Despite more than 95 percent of isolates being piperacillin-tazobactam susceptible by microdilution, the microbiological failure among the group that received piperacillin-tazobactam was greater (5 of 38; 13 percent) than the group that received meropenem (0 of 34). </p><p>The findings of this trial are also consistent with earlier reports of treatment failure with <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> and some observational studies suggesting inferiority to carbapenems [<a href="#rid65">65,88-91</a>]. As an example, in a retrospective study of over 200 individuals with bacteremia due to an ESBL-producing organism, empiric treatment with piperacillin-tazobactam was associated with a higher risk of death within 14 days compared with a carbapenem (adjusted hazard ratio [HR] 1.92, 95% CI 1.07-3.45) [<a href="#rid69">69</a>]. </p><p>However, other observational studies had suggested no difference in mortality among patients (including neutropenic patients) with ESBL-producing <em>E. coli</em> bacteremia treated with either <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> or a carbapenem for empiric or definitive therapy [<a href="#rid92">92,93</a>]. In light of the trial findings above and the greater potential for confounding in observational studies, these results should not be used to support use of piperacillin-tazobactam for bloodstream infections.</p><p>In addition to concerns about efficacy of <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> for ESBL-producing isolates, resistance may develop during therapy [<a href="#rid89">89</a>]. </p><p class="headingAnchor" id="H21"><span class="h3">Other drugs</span><span class="headingEndMark"> — </span>Data on other agents for use in for ESBL-producing organisms are sparse. </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">Tigecycline</a> is a non-beta-lactam drug that is a potential alternative for treatment of ESBL-producing strains, especially for patients with beta-lactam allergies, although data on its clinical use for this purpose are limited. In a systematic review of 10 studies that included 33 patients who received tigecycline for an ESBL infection, the response rate was 67 percent [<a href="#rid94">94</a>]. Increasing tigecycline resistance does not yet appear to be a problem, as a 2014 microbiological surveillance showed unchanged resistance profiles in 2012 when compared with 2006 isolates [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">Eravacycline</a> also appears effective against ESBL-producing isolates, based on limited clinical data. In an analysis of two randomized trials that demonstrated comparable clinical outcomes for complicated intra-abdominal infections with either intravenous eravacycline or a carbapenem, microbiologic and clinical cure rates with eravacycline for the 36 infections due to an ESBL-producing Enterobacteriaceae were 89 and 86 percent, respectively [<a href="#rid62">62</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">Plazomicin</a> is an advanced aminoglycoside that often retains activity against ESBL-producing isolates despite the presence of aminoglycoside-modifying enzymes that inactivate other aminoglycosides. In a randomized trial of 609 patients with acute complicated urinary tract infection (including pyelonephritis and infections complicated by bacteremia), early clinical cure rates with plazomicin were similar to those with <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (88 versus 91 percent); among the 120 patients with infection caused by an isolate with an ESBL phenotype, microbial eradication rates at two weeks were also similar (82 versus 75 percent with meropenem) [<a href="#rid96">96</a>]. A ≥0.5 mg/dL increase in serum creatinine over baseline occurred in 7 versus 4 percent with plazomicin and meropenem, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">Fosfomycin</a> retains activity against many ESBL-producing isolates, and oral fosfomycin can be effective for cystitis caused by ESBL-producing <em>E. coli</em>, although emergent resistance may be a concern [<a href="#rid97">97,98</a>]. This is discussed elsewhere (see  <a class="medical medical_review" href="/z/d/html/8063.html" rel="external">"Acute simple cystitis in adult and adolescent females", section on 'Patients with MDR risk factors'</a>). Intravenous fosfomycin is also a potential option that is active against many ESBL-producing organisms and is effective in complicated UTIs, but it is not widely available [<a href="#rid99">99</a>]. </p><p></p><p>There are no clinical data supporting the use of double antibiotic coverage for treatment of ESBL-producing organisms.</p><p class="headingAnchor" id="H20111594"><span class="h1">DURATION OF THERAPY</span><span class="headingEndMark"> — </span>Infection with an extended-spectrum beta-lactamase (ESBL)-producing organism usually does not warrant a longer course of therapy than generally indicated for the type of infection. Duration of therapy for specific infections is discussed separately in the corresponding topic reviews. (See  <a class="medical medical_review" href="/z/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Duration and route of therapy'</a> and  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Management'</a> and  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults", section on 'Duration'</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Studies evaluating clinical outcomes in patients with extended-spectrum beta-lactamase (ESBL) infections have shown a trend toward higher mortality, longer hospital stay, greater hospital expenses, and reduced rates of clinical and microbiologic response [<a href="#rid65">65,100-102</a>]. In a meta-analysis of 32 studies of bacteremia with Enterobacteriaceae, infection with ESBL-producing organisms was associated with higher mortality than non-ESBL-producing organisms, (OR 2.35, 95% CI 1.90-2.91) [<a href="#rid103">103</a>]. Evaluation of the studies that performed adjusted analyses suggested that much of the increased mortality may be due to ineffective empiric therapy. As mentioned above, mortality rates of 3.7 percent have been described with carbapenems, with much higher mortality rates with antibiotics not active against these organisms (7 of 11 [64 percent]) and with cephalosporin monotherapy or a beta-lactam/beta-lactamase inhibitor combination such as <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> (4 of 9 [44 percent]) [<a href="#rid65">65</a>]. </p><p>In one predictive model for mortality among patients with bloodstream infections with ESBL-producing organisms, factors with a major impact on mortality include age older than 50 years, infection due to <em>Klebsiella</em> spp, source other than urinary tract, fatal underlying disease, Pitt score &gt;3, severe sepsis or septic shock at presentation, and inappropriate empirical antibiotic choice [<a href="#rid104">104</a>].</p><p>Some individuals infected or colonized by ESBL-producing organisms continue to shed bacteria for prolonged periods [<a href="#rid105">105</a>]. Among 42 patients with infection due to ESBL-producing <em>E. coli</em>, persistent colonization was observed after a median of 58 months among five patients. It is unclear whether systemic antibiotic therapy affects colonization status. </p><p class="headingAnchor" id="H23"><span class="h1">INFECTION CONTROL AND ANTIBIOTIC STEWARDSHIP</span><span class="headingEndMark"> — </span>As with other clonal outbreaks caused by multidrug-resistant gram-negative rods, interventions aimed at controlling the horizontal spread of extended-spectrum beta-lactamase (ESBL)-producing organisms should target the transmission pathways within the hospital. Two main strategies to control outbreaks due to ESBL-producing bacteria have been described: barrier protection of infected or colonized patients (contact precautions), and restriction of beta-lactam use [<a href="#rid101">101,106</a>]. The optimal implementation of contact precautions is uncertain. We agree with guidelines from the Society for Healthcare Epidemiology that recommend contact precautions for the duration of the hospitalization during which ESBL infection or colonization was identified [<a href="#rid107">107</a>]. Discontinuation of inpatient contact precautions can be considered once six months have passed since the last positive culture, the patient does not have an active infection and is not on active treatment of an ESBL infection, and at least two consecutive negative rectal swabs at least one week apart, off antibiotics, have been obtained. </p><p>Institution of both barrier protection and restriction of cephalosporin use in one study was associated with a decrease in the number of infections caused by ESBL-producing <em>K. pneumoniae</em> (4.9 episodes to 0.6 episodes per 1000 patient-days) [<a href="#rid106">106</a>]. In a 2017 meta-analysis, antimicrobial stewardship programs reduced the incidence of ESBL-producing Enterobacteriaceae colonization and infection by 48 percent [<a href="#rid108">108</a>]. The institution of barrier methods without antibiotic restriction has also been evaluated [<a href="#rid31">31,109</a>]. All personnel in contact with patients infected with or carriers of ESBL-producing Enterobacteriaceae were required to use gowns and gloves. In one study, barrier production was associated with a decrease in the incidence of hospital-acquired ESBL from 172 patients to 19 over three years, despite increased use of cephalosporins [<a href="#rid109">109</a>]. </p><p>A subsequent study modeled the impact of improved hand hygiene, patient cohorting, and antibiotic restrictions [<a href="#rid110">110</a>]. Improving hand hygiene compliance from 60 to 80 percent would be associated with a 91 percent reduction in colonization with ESBL-producing gram-negative rods at 90 days. Cohorting patients would be associated with a further 7 percent decrease in colonization rates. However, antibiotic restriction would not affect colonization rates.</p><p>Since there are environmental reservoirs for resistant gram-negative organisms (eg, sink pipes), ensuring the cleanliness of medical equipment and patient care areas are also important measures for prevention and reduction of healthcare-associated infection. (See  <a class="medical medical_review" href="/z/d/html/101613.html" rel="external">"Infection prevention: General principles", section on 'Cleaning, disinfection, and sterilization'</a>.)</p><p class="headingAnchor" id="H20111524"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic resistance due to extended-spectrum beta-lactamases (ESBLs)</strong> – ESBLs are enzymes that inactivate and confer resistance to most beta-lactam antibiotics, including penicillins, cephalosporins, and the monobactam <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>. They are found exclusively in gram-negative organisms, primarily <em>Klebsiella pneumoniae</em>, <em>Klebsiella oxytoca</em>, and <em>Escherichia coli</em>. Many different varieties of ESBL exist. They differ in their activity against particular beta-lactam substrates and in their geographical distribution. Most ESBLs do not break down cephamycins or carbapenems and are susceptible to beta-lactamase inhibitors. (See <a class="local">'Introduction'</a> above and <a class="local">'Extended-spectrum beta-lactamases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Identifying ESBLs</strong> – Laboratory detection of an ESBL in an organism is based on resistance to particular cephalosporins and the ability of a beta-lactamase inhibitor to block this resistance. However, the heterogeneity of the ESBL varieties can make identification difficult. Thus, the Clinical and Laboratory Standards Institute has adjusted susceptibility breakpoint recommendations for gram-negative bacilli. As a result, many organisms that previously would have been categorized as susceptible using the former breakpoints may now be considered intermediate or resistant. This often precludes the need to identify the ESBL in order to make treatment decisions. (See <a class="local">'Laboratory detection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and risk factors</strong> – ESBL-producing gram-negative bacilli have been reported worldwide. They are most often isolated from hospitalized patients but are an increasing cause of community-acquired infections. Risk factors for infection include prior administration of an antibiotic, presence of urinary or vascular catheters, and longer hospital or ICU stays. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic selection</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Carbapenems as preferred agents</strong> – We suggest <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> or <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> for ESBL infections, rather than other beta-lactam agents such as <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> and <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">Ertapenem</a> is an acceptable option in the absence of resistance or severe sepsis and can be particularly useful in the outpatient setting. (See <a class="local">'Preferred agents'</a> above and <a class="local">'Clinical efficacy'</a> above.)</p><p></p><p class="bulletIndent2">Use of cephalosporins and <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> has been associated with treatment failures or higher mortality rates. Fluoroquinolones can be used to treat susceptible isolates but resistance is common.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternative agents</strong> – <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">Plazomicin</a> often retains activity despite resistance to other aminoglycosides and is effective for complicated urinary tract infection (UTI). <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">Ceftolozane-tazobactam</a>, <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, and <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">eravacycline</a> appear promising, but further clinical data are needed to establish their efficacy relative to carbapenems. There is little clinical evidence for cephamycin use, which has been associated with development of resistance. (See <a class="local">'Treatment options'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Infections with ESBL-producing organisms are associated with higher mortality rates, longer hospital stays, greater hospital expenses, and reduced rates of clinical and microbiologic response compared with similar infections with gram-negative bacteria that do not produce ESBL. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection control</strong> – The spread of ESBL-producing organisms within institutions can be slowed by the use of barrier protection and restriction of later generation cephalosporins. (See <a class="local">'Infection control and antibiotic stewardship'</a> above.)</p><p></p><p><strong>ACKNOWLEDGMENT</strong> — The UpToDate editorial staff acknowledges George A Jacoby, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ben-Ami R, Rodríguez-Baño J, Arslan H, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49:682.</a></li><li><a class="nounderline abstract_t">Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14:933.</a></li><li><a class="nounderline abstract_t">Kliebe C, Nies BA, Meyer JF, et al. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1985; 28:302.</a></li><li><a class="nounderline abstract_t">Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657.</a></li><li><a class="nounderline abstract_t">Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013; 56:641.</a></li><li><a class="nounderline abstract_t">Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352:380.</a></li><li><a class="nounderline abstract_t">Castanheira M, Farrell SE, Deshpande LM, et al. Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob Agents Chemother 2013; 57:3012.</a></li><li class="breakAll">ß-lactamase classification and amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant enzymes. Lahey Clinic http://www.lahey.org/Studies/ (Accessed on May 14, 2015).</li><li><a class="nounderline abstract_t">Cantón R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006; 9:466.</a></li><li><a class="nounderline abstract_t">Lascols C, Hackel M, Hujer AM, et al. Using nucleic acid microarrays to perform molecular epidemiology and detect novel β-lactamases: a snapshot of extended-spectrum β-lactamases throughout the world. J Clin Microbiol 2012; 50:1632.</a></li><li><a class="nounderline abstract_t">D'Andrea MM, Arena F, Pallecchi L, Rossolini GM. CTX-M-type β-lactamases: a successful story of antibiotic resistance. Int J Med Microbiol 2013; 303:305.</a></li><li><a class="nounderline abstract_t">Endimiani A, Luzzaro F, Pini B, et al. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infect Dis 2006; 6:52.</a></li><li class="breakAll">National Committee for Clinical Laboratory Standards, Wayne, PA 1999.</li><li class="breakAll">Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement; M100-S20. June 2010 Update. Clinical and Laboratory Standards Institute, Wayne, PA</li><li class="breakAll">European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1. EUCAST, 2010. http://www.eucast.org/clinical_breakpoints/ (Accessed on May 16, 2012).</li><li><a class="nounderline abstract_t">Hombach M, Bloemberg GV, Böttger EC. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli. J Antimicrob Chemother 2012; 67:622.</a></li><li><a class="nounderline abstract_t">Thomson KS. Lowering of third generation cephalosporin breakpoints. Clin Infect Dis 2013; 57:1663.</a></li><li><a class="nounderline abstract_t">Livermore DM, Andrews JM, Hawkey PM, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 2012; 67:1569.</a></li><li class="breakAll">Clinical and Laboratory Standards Institute. 2015. M100-S25: Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement; M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA. http://shop.clsi.org/c.1253739/site/Sample_pdf/M100S25_sample.pdf (Accessed on May 14, 2015).</li><li><a class="nounderline abstract_t">Gazin M, Paasch F, Goossens H, et al. Current trends in culture-based and molecular detection of extended-spectrum-β-lactamase-harboring and carbapenem-resistant Enterobacteriaceae. J Clin Microbiol 2012; 50:1140.</a></li><li><a class="nounderline abstract_t">Castanheira M, Farrell SE, Krause KM, et al. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrob Agents Chemother 2014; 58:833.</a></li><li><a class="nounderline abstract_t">Thaden JT, Fowler VG, Sexton DJ, Anderson DJ. Increasing Incidence of Extended-Spectrum β-Lactamase-Producing Escherichia coli in Community Hospitals throughout the Southeastern United States. Infect Control Hosp Epidemiol 2016; 37:49.</a></li><li><a class="nounderline abstract_t">Morrissey I, Hackel M, Badal R, et al. A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals (Basel) 2013; 6:1335.</a></li><li><a class="nounderline abstract_t">Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int J Antimicrob Agents 2014; 43:328.</a></li><li><a class="nounderline abstract_t">Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012; 73:354.</a></li><li><a class="nounderline abstract_t">Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum β-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev 2013; 26:744.</a></li><li><a class="nounderline abstract_t">Karanika S, Karantanos T, Arvanitis M, et al. Fecal Colonization With Extended-spectrum Beta-lactamase-Producing Enterobacteriaceae and Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis. Clin Infect Dis 2016; 63:310.</a></li><li><a class="nounderline abstract_t">Lukac PJ, Bonomo RA, Logan LK. Extended-spectrum β-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat. Clin Infect Dis 2015; 60:1389.</a></li><li><a class="nounderline abstract_t">Logan LK, Braykov NP, Weinstein RA, et al. Extended-Spectrum β-Lactamase-Producing and Third-Generation Cephalosporin-Resistant Enterobacteriaceae in Children: Trends in the United States, 1999-2011. J Pediatric Infect Dis Soc 2014; 3:320.</a></li><li><a class="nounderline abstract_t">Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281:517.</a></li><li><a class="nounderline abstract_t">Tschudin-Sutter S, Frei R, Dangel M, et al. Rate of transmission of extended-spectrum beta-lactamase-producing enterobacteriaceae without contact isolation. Clin Infect Dis 2012; 55:1505.</a></li><li><a class="nounderline abstract_t">Hilty M, Betsch BY, Bögli-Stuber K, et al. Transmission dynamics of extended-spectrum β-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. Clin Infect Dis 2012; 55:967.</a></li><li><a class="nounderline abstract_t">Madigan T, Johnson JR, Clabots C, et al. Extensive Household Outbreak of Urinary Tract Infection and Intestinal Colonization due to Extended-Spectrum β-Lactamase-Producing Escherichia coli Sequence Type 131. Clin Infect Dis 2015; 61:e5.</a></li><li><a class="nounderline abstract_t">Korzeniewska E, Harnisz M. Extended-spectrum beta-lactamase (ESBL)-positive Enterobacteriaceae in municipal sewage and their emission to the environment. J Environ Manage 2013; 128:904.</a></li><li><a class="nounderline abstract_t">Gomi R, Matsuda T, Matsumura Y, et al. Occurrence of Clinically Important Lineages, Including the Sequence Type 131 C1-M27 Subclone, among Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Wastewater. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Kotay S, Chai W, Guilford W, et al. Spread from the Sink to the Patient: In Situ Study Using Green Fluorescent Protein (GFP)-Expressing Escherichia coli To Model Bacterial Dispersion from Hand-Washing Sink-Trap Reservoirs. Appl Environ Microbiol 2017; 83.</a></li><li><a class="nounderline abstract_t">Simões RR, Poirel L, Da Costa PM, Nordmann P. Seagulls and beaches as reservoirs for multidrug-resistant Escherichia coli. Emerg Infect Dis 2010; 16:110.</a></li><li><a class="nounderline abstract_t">Poirel L, Potron A, De La Cuesta C, et al. Wild coastline birds as reservoirs of broad-spectrum-β-lactamase-producing Enterobacteriaceae in Miami Beach, Florida. Antimicrob Agents Chemother 2012; 56:2756.</a></li><li><a class="nounderline abstract_t">Reist M, Geser N, Hächler H, et al. ESBL-producing Enterobacteriaceae: occurrence, risk factors for fecal carriage and strain traits in the Swiss slaughter cattle population younger than 2 years sampled at abattoir level. PLoS One 2013; 8:e71725.</a></li><li><a class="nounderline abstract_t">Hammerum AM, Larsen J, Andersen VD, et al. Characterization of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli obtained from Danish pigs, pig farmers and their families from farms with high or no consumption of third- or fourth-generation cephalosporins. J Antimicrob Chemother 2014; 69:2650.</a></li><li><a class="nounderline abstract_t">Ewers C, Bethe A, Semmler T, et al. Extended-spectrum β-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: a global perspective. Clin Microbiol Infect 2012; 18:646.</a></li><li><a class="nounderline abstract_t">Poirel L, Nordmann P, Ducroz S, et al. Extended-spectrum β-lactamase CTX-M-15-producing Klebsiella pneumoniae of sequence type ST274 in companion animals. Antimicrob Agents Chemother 2013; 57:2372.</a></li><li><a class="nounderline abstract_t">Doi Y, Paterson DL, Egea P, et al. Extended-spectrum and CMY-type beta-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain. Clin Microbiol Infect 2010; 16:33.</a></li><li><a class="nounderline abstract_t">Kluytmans JA, Overdevest IT, Willemsen I, et al. Extended-spectrum β-lactamase-producing Escherichia coli from retail chicken meat and humans: comparison of strains, plasmids, resistance genes, and virulence factors. Clin Infect Dis 2013; 56:478.</a></li><li><a class="nounderline abstract_t">Liebana E, Carattoli A, Coque TM, et al. Public health risks of enterobacterial isolates producing extended-spectrum β-lactamases or AmpC β-lactamases in food and food-producing animals: an EU perspective of epidemiology, analytical methods, risk factors, and control options. Clin Infect Dis 2013; 56:1030.</a></li><li><a class="nounderline abstract_t">Calbo E, Freixas N, Xercavins M, et al. Foodborne nosocomial outbreak of SHV1 and CTX-M-15-producing Klebsiella pneumoniae: epidemiology and control. Clin Infect Dis 2011; 52:743.</a></li><li><a class="nounderline abstract_t">Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections. Ann Intern Med 2004; 140:26.</a></li><li><a class="nounderline abstract_t">Park YS, Adams-Haduch JM, Shutt KA, et al. Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States. Antimicrob Agents Chemother 2012; 56:1870.</a></li><li><a class="nounderline abstract_t">Kang CI, Wi YM, Lee MY, et al. Epidemiology and risk factors of community onset infections caused by extended-spectrum β-lactamase-producing Escherichia coli strains. J Clin Microbiol 2012; 50:312.</a></li><li><a class="nounderline abstract_t">Rodríguez-Baño J, Picón E, Gijón P, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010; 50:40.</a></li><li><a class="nounderline abstract_t">Bert F, Larroque B, Paugam-Burtz C, et al. Pretransplant fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae and infection after liver transplant, France. Emerg Infect Dis 2012; 18:908.</a></li><li><a class="nounderline abstract_t">Lee JA, Kang CI, Joo EJ, et al. Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Microb Drug Resist 2011; 17:267.</a></li><li><a class="nounderline abstract_t">Tängdén T, Cars O, Melhus A, Löwdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010; 54:3564.</a></li><li><a class="nounderline abstract_t">Arcilla MS, van Hattem JM, Haverkate MR, et al. Import and spread of extended-spectrum β-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study. Lancet Infect Dis 2017; 17:78.</a></li><li><a class="nounderline abstract_t">Strysko JP, Mony V, Cleveland J, et al. International travel is a risk factor for extended-spectrum β-lactamase-producing Enterobacteriaceae acquisition in children: A case-case-control study in an urban U.S. hospital. Travel Med Infect Dis 2016; 14:568.</a></li><li><a class="nounderline abstract_t">Reuland EA, Sonder GJ, Stolte I, et al. Travel to Asia and traveller's diarrhoea with antibiotic treatment are independent risk factors for acquiring ciprofloxacin-resistant and extended spectrum β-lactamase-producing Enterobacteriaceae-a prospective cohort study. Clin Microbiol Infect 2016; 22:731.e1.</a></li><li><a class="nounderline abstract_t">Kantele A, Lääveri T, Mero S, et al. Antimicrobials increase travelers' risk of colonization by extended-spectrum betalactamase-producing Enterobacteriaceae. Clin Infect Dis 2015; 60:837.</a></li><li><a class="nounderline abstract_t">Goodman KE, Lessler J, Cosgrove SE, et al. A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrum β-Lactamase-Producing Organism. Clin Infect Dis 2016; 63:896.</a></li><li><a class="nounderline abstract_t">Levasseur P, Girard AM, Miossec C, et al. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized β-lactamases. Antimicrob Agents Chemother 2015; 59:1931.</a></li><li><a class="nounderline abstract_t">Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother 2013; 57:6305.</a></li><li><a class="nounderline abstract_t">Harris PN, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis 2015; 15:475.</a></li><li class="breakAll">Newman J, Izmailyan S, Fyfe C, Tsai, L. Microbiological Efficacy of Eravacycline against Enterobacteriaceae And Acinetobacter, Including Mdr Isolates: A Pooled Analysis from Ignite1 and Ignite4, Two Phase 3 Trials of Complicated Intra-Abdominal Infection. Presented at ASM Microbe 2018, June 7-11 2018, Atlanta GA.</li><li><a class="nounderline abstract_t">Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45:3548.</a></li><li><a class="nounderline abstract_t">Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens. Antimicrob Agents Chemother 1997; 41:1830.</a></li><li><a class="nounderline abstract_t">Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31.</a></li><li><a class="nounderline abstract_t">Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206.</a></li><li><a class="nounderline abstract_t">Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial. JAMA 2018; 320:984.</a></li><li><a class="nounderline abstract_t">Endimiani A, Luzzaro F, Perilli M, et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004; 38:243.</a></li><li><a class="nounderline abstract_t">Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia. Clin Infect Dis 2015; 60:1319.</a></li><li><a class="nounderline abstract_t">Collins VL, Marchaim D, Pogue JM, et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2012; 56:2173.</a></li><li><a class="nounderline abstract_t">Lee NY, Lee CC, Huang WH, et al. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility. Antimicrob Agents Chemother 2012; 56:2888.</a></li><li><a class="nounderline abstract_t">Berg ML, Crank CW, Philbrick AH, Hayden MK. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report. Ann Pharmacother 2008; 42:207.</a></li><li><a class="nounderline abstract_t">Bazaz R, Chapman AL, Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. J Antimicrob Chemother 2010; 65:1510.</a></li><li><a class="nounderline abstract_t">Fong JJ, Rosé L, Radigan EA. Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing gram-negative bacteria. Ann Pharmacother 2012; 46:347.</a></li><li><a class="nounderline abstract_t">Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, et al. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother 2016; 71:1672.</a></li><li><a class="nounderline abstract_t">Lartigue MF, Poirel L, Poyart C, et al. Ertapenem resistance of Escherichia coli. Emerg Infect Dis 2007; 13:315.</a></li><li><a class="nounderline abstract_t">Lee NY, Lee CC, Huang WH, et al. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013; 56:488.</a></li><li><a class="nounderline abstract_t">Sader HS, Castanheira M, Flamm RK, et al. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents 2015; 46:53.</a></li><li><a class="nounderline abstract_t">Chopra T, Marchaim D, Veltman J, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 2012; 56:3936.</a></li><li><a class="nounderline abstract_t">Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47:3442.</a></li><li><a class="nounderline abstract_t">Goethaert K, Van Looveren M, Lammens C, et al. High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients. Clin Microbiol Infect 2006; 12:56.</a></li><li><a class="nounderline abstract_t">Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infect 2005; 51:211.</a></li><li><a class="nounderline abstract_t">Seo YB, Lee J, Kim YK, et al. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli. BMC Infect Dis 2017; 17:404.</a></li><li><a class="nounderline abstract_t">Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis 2015; 60:1462.</a></li><li><a class="nounderline abstract_t">Sternbach N, Leibovici Weissman Y, Avni T, Yahav D. Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis. J Antimicrob Chemother 2018; 73:2021.</a></li><li><a class="nounderline abstract_t">Gavin PJ, Suseno MT, Thomson RB Jr, et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother 2006; 50:2244.</a></li><li><a class="nounderline abstract_t">Stewart AG, Paterson DL, Young B, et al. Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2). Open Forum Infect Dis 2021; 8:ofab387.</a></li><li><a class="nounderline abstract_t">Wong-Beringer A, Hindler J, Loeloff M, et al. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin Infect Dis 2002; 34:135.</a></li><li><a class="nounderline abstract_t">Zimhony O, Chmelnitsky I, Bardenstein R, et al. Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother 2006; 50:3179.</a></li><li><a class="nounderline abstract_t">Paterson DL, Singh N, Gayowski T, Marino IR. Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis. Clin Infect Dis 1999; 28:683.</a></li><li><a class="nounderline abstract_t">Ofer-Friedman H, Shefler C, Sharma S, et al. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. Infect Control Hosp Epidemiol 2015; 36:981.</a></li><li><a class="nounderline abstract_t">Rodríguez-Baño J, Navarro MD, Retamar P, et al. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012; 54:167.</a></li><li><a class="nounderline abstract_t">Gudiol C, Royo-Cebrecos C, Abdala E, et al. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother 2008; 62:895.</a></li><li><a class="nounderline abstract_t">Sader HS, Farrell DJ, Flamm RK, Jones RN. Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). Antimicrob Agents Chemother 2014; 58:2274.</a></li><li><a class="nounderline abstract_t">Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med 2019; 380:729.</a></li><li><a class="nounderline abstract_t">Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10:43.</a></li><li><a class="nounderline abstract_t">Neuner EA, Sekeres J, Hall GS, van Duin D. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms. Antimicrob Agents Chemother 2012; 56:5744.</a></li><li><a class="nounderline abstract_t">Kaye KS, Rice LB, Dane AL, et al. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis 2019; 69:2045.</a></li><li><a class="nounderline abstract_t">Lautenbach E, Patel JB, Bilker WB, et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162.</a></li><li><a class="nounderline abstract_t">Meyer KS, Urban C, Eagan JA, et al. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119:353.</a></li><li><a class="nounderline abstract_t">Tumbarello M, Spanu T, Sanguinetti M, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50:498.</a></li><li><a class="nounderline abstract_t">Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 2012; 67:1311.</a></li><li><a class="nounderline abstract_t">Palacios-Baena ZR, Gutiérrez-Gutiérrez B, De Cueto M, et al. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2017; 72:906.</a></li><li><a class="nounderline abstract_t">Alsterlund R, Axelsson C, Olsson-Liljequist B. Long-term carriage of extended-spectrum beta-lactamase-producing Escherichia coli. Scand J Infect Dis 2012; 44:51.</a></li><li><a class="nounderline abstract_t">Peña C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42:53.</a></li><li><a class="nounderline abstract_t">Banach DB, Bearman G, Barnden M, et al. Duration of Contact Precautions for Acute-Care Settings. Infect Control Hosp Epidemiol 2018; 39:127.</a></li><li><a class="nounderline abstract_t">Baur D, Gladstone BP, Burkert F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 2017; 17:990.</a></li><li><a class="nounderline abstract_t">Lucet JC, Decré D, Fichelle A, et al. Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital. Clin Infect Dis 1999; 29:1411.</a></li><li><a class="nounderline abstract_t">Pelat C, Kardaś-Słoma L, Birgand G, et al. Hand Hygiene, Cohorting, or Antibiotic Restriction to Control Outbreaks of Multidrug-Resistant Enterobacteriaceae. Infect Control Hosp Epidemiol 2016; 37:272.</a></li></ol></div><div id="topicVersionRevision">Topic 469 Version 49.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19622043" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11585791" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3879659" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evolution of plasmid-coded resistance to broad-spectrum cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16223952" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Extended-spectrum beta-lactamases: a clinical update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150211" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Community-associated extended-spectrumβ-lactamase-producing Escherichia coli infection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15673804" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The new beta-lactamases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23587957" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Prevalence ofβ-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23587957" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Prevalence ofβ-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16942899" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The CTX-M beta-lactamase pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22322349" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Using nucleic acid microarrays to perform molecular epidemiology and detect novelβ-lactamases: a snapshot of extended-spectrumβ-lactamases throughout the world.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23490927" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : CTX-M-typeβ-lactamases: a successful story of antibiotic resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16542460" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16542460" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16542460" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16542460" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22167240" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24006448" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Lowering of third generation cephalosporin breakpoints.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22461311" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22461311" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22259207" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Current trends in culture-based and molecular detection of extended-spectrum-β-lactamase-harboring and carbapenem-resistant Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24247134" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Contemporary diversity ofβ-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalentβ-lactamase groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26458226" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Increasing Incidence of Extended-Spectrumβ-Lactamase-Producing Escherichia coli in Community Hospitals throughout the Southeastern United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24287460" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24630306" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22656912" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092853" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Trends in human fecal carriage of extended-spectrumβ-lactamases in the community: toward the globalization of CTX-M.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27143671" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fecal Colonization With Extended-spectrum Beta-lactamase-Producing Enterobacteriaceae and Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25595742" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Extended-spectrumβ-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26625452" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Extended-Spectrumβ-Lactamase-Producing and Third-Generation Cephalosporin-Resistant Enterobacteriaceae in Children: Trends in the United States, 1999-2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022107" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22955436" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Rate of transmission of extended-spectrum beta-lactamase-producing enterobacteriaceae without contact isolation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22718774" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Transmission dynamics of extended-spectrumβ-lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25828998" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Extensive Household Outbreak of Urinary Tract Infection and Intestinal Colonization due to Extended-Spectrumβ-Lactamase-Producing Escherichia coli Sequence Type 131.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23886578" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Extended-spectrum beta-lactamase (ESBL)-positive Enterobacteriaceae in municipal sewage and their emission to the environment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28630184" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Occurrence of Clinically Important Lineages, Including the Sequence Type 131 C1-M27 Subclone, among Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Wastewater.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28235877" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Spread from the Sink to the Patient: In Situ Study Using Green Fluorescent Protein (GFP)-Expressing Escherichia coli To Model Bacterial Dispersion from Hand-Washing Sink-Trap Reservoirs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031053" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Seagulls and beaches as reservoirs for multidrug-resistant Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22314536" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Wild coastline birds as reservoirs of broad-spectrum-β-lactamase-producing Enterobacteriaceae in Miami Beach, Florida.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23977126" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : ESBL-producing Enterobacteriaceae: occurrence, risk factors for fecal carriage and strain traits in the Swiss slaughter cattle population younger than 2 years sampled at abattoir level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24908045" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Characterization of extended-spectrumβ-lactamase (ESBL)-producing Escherichia coli obtained from Danish pigs, pig farmers and their families from farms with high or no consumption of third- or fourth-generation cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22519858" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Extended-spectrumβ-lactamase-producing and AmpC-producing Escherichia coli from livestock and companion animals, and their putative impact on public health: a global perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23422912" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Extended-spectrumβ-lactamase CTX-M-15-producing Klebsiella pneumoniae of sequence type ST274 in companion animals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19681957" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Extended-spectrum and CMY-type beta-lactamase-producing Escherichia coli in clinical samples and retail meat from Pittsburgh, USA and Seville, Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23243181" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Extended-spectrumβ-lactamase-producing Escherichia coli from retail chicken meat and humans: comparison of strains, plasmids, resistance genes, and virulence factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23243183" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Public health risks of enterobacterial isolates producing extended-spectrumβ-lactamases or AmpCβ-lactamases in food and food-producing animals: an EU perspective of epidemiology, analytical methods, risk factors, and control options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367727" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Foodborne nosocomial outbreak of SHV1 and CTX-M-15-producing Klebsiella pneumoniae: epidemiology and control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14706969" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22290945" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical and microbiologic characteristics of cephalosporin-resistant Escherichia coli at three centers in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22162561" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Epidemiology and risk factors of community onset infections caused by extended-spectrumβ-lactamase-producing Escherichia coli strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19995215" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22607885" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pretransplant fecal carriage of extended-spectrumβ-lactamase-producing Enterobacteriaceae and infection after liver transplant, France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21388296" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Epidemiology and clinical features of community-onset bacteremia caused by extended-spectrumβ-lactamase-producing Klebsiella pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20547788" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27751772" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Import and spread of extended-spectrumβ-lactamase-producing Enterobacteriaceae by international travellers (COMBAT study): a prospective, multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27890813" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : International travel is a risk factor for extended-spectrumβ-lactamase-producing Enterobacteriaceae acquisition in children: A case-case-control study in an urban U.S. hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27223840" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Travel to Asia and traveller's diarrhoea with antibiotic treatment are independent risk factors for acquiring ciprofloxacin-resistant and extended spectrumβ-lactamase-producing Enterobacteriaceae-a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25613287" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antimicrobials increase travelers' risk of colonization by extended-spectrum betalactamase-producing Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27358356" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A Clinical Decision Tree to Predict Whether a Bacteremic Patient Is Infected With an Extended-Spectrumβ-Lactamase-Producing Organism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25583732" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterizedβ-lactamases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24100499" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25716293" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : β-lactam andβ-lactamase inhibitor combinations in the treatment of extended-spectrumβ-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25716293" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : β-lactam andβ-lactamase inhibitor combinations in the treatment of extended-spectrumβ-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11709338" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9257772" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15206050" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11376058" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30208454" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14699457" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25586681" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrumβ-lactamase bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22290982" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22430969" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18230703" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase-producing gram-negative infections: a case series report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20460397" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22395250" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrumβ-lactamase producing gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26907184" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17479901" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Ertapenem resistance of Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23090931" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25956844" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22547616" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576100" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16460547" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230218" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clinical implications of extended spectrum beta-lactamase (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28592240" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25670823" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29659836" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16723596" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34395716" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpCβ-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11740699" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940124" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Endocarditis caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10194100" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25990361" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22057701" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrumβ-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28584145" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Efficacy ofβ-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18676620" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24492361" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30786187" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Once-Daily Plazomicin for Complicated Urinary Tract Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20129148" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22926565" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30861061" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283805" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8135915" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16436702" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22396430" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrumβ-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28062685" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21736509" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Long-term carriage of extended-spectrum beta-lactamase-producing Escherichia coli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9449260" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29321078" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Duration of Contact Precautions for Acute-Care Settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28629876" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585788" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Control of a prolonged outbreak of extended-spectrum beta-lactamase-producing enterobacteriaceae in a university hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26708383" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Hand Hygiene, Cohorting, or Antibiotic Restriction to Control Outbreaks of Multidrug-Resistant Enterobacteriaceae.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
